Browse > Article
http://dx.doi.org/10.3831/KPI.2019.22.013

Antiproliferative Effects of Free and Encapsulated Hypericum Perforatum L. Extract and Its Potential Interaction with Doxorubicin for Esophageal Squamous Cell Carcinoma  

Amjadi, Issa (Department of Biomedical Engineering, Wayne State University)
Mohajeri, Mohammad (Department of Medical Biotechnology, Mashhad University of Medical Sciences)
Borisov, Andrei (Department of Biomedical Engineering, Wayne State University)
Hosseini, Motahare-Sadat (Biomaterials Group, Department of Biomedical Engineering, Amirkabir University of Technology)
Publication Information
Journal of Pharmacopuncture / v.22, no.2, 2019 , pp. 102-108 More about this Journal
Abstract
Objectives: Esophageal squamous cell carcinoma (ESCC) is considered as a deadly medical condition that affects a growing number of people worldwide. Targeted therapy of ESCC has been suggested recently and required extensive research. With cyclin D1 as a therapeutic target, the present study aimed at evaluating the anticancer effects of doxorubicin (Dox) or Hypericum perforatum L. (HP) extract encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles on the ESCC cell line KYSE30. Methods: Nanoparticles were prepared using double emulsion method. Cytotoxicity assay was carried out to measure the anti-proliferation activity of Dox-loaded (Dox NPs) and HP-loaded nanoparticles (HP NPs) against both cancer and normal cell lines. The mRNA gene expression of cyclin D1 was evaluated to validate the cytotoxicity studies at molecular level. Results: Free drugs and nanoparticles significantly inhibited KYSE30 cells by 55-73% and slightly affected normal cells up to 29%. The IC50 of Dox NPs and HP NPs was ~ 0.04-0.06 mg/mL and ~ 0.6-0.7 mg/mL, respectively. Significant decrease occurred in cyclin D1 expression by Dox NPs and HP NPs (P < 0.05). Exposure of KYSE-30 cells to combined treatments including both Dox and HP extract significantly increased the level of cyclin D1 expression as compared to those with individual treatments (P < 0.05). Conclusion: Dox NPs and HP NPs can successfully and specifically target ESCC cells through downregulation of cyclin D1. The simultaneous use of Dox and HP extract should be avoided for the treatment of ESCC.
Keywords
doxorubicin; hypericum perforatum extract; nanoparticles; esophageal squamous cell carcinoma; drug resistance;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Malek M, Aghili R, Emami Z, Khamseh ME. Risk of cancer in diabetes: the effect of metformin. ISRN endocrinology. 2013;2013:636927.   DOI
2 Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine: Nanotechnology, Biology and Medicine. 2007;3(4):246-257.   DOI
3 Abbas G, Krasna M. Overview of esophageal cancer. Annals of cardiothoracic surgery. 2017;6(2):131-136.   DOI
4 Chen Z, Ren Y, Du XL, Yang J, Shen Y, Li S, et al. Incidence and survival differences in esophageal cancer among ethnic groups in the United States. Oncotarget. 2017;8(29):47037-47051.   DOI
5 Lin DC, Du XL, Wang MR. Protein alterations in ESCC and clinical implications: a review. Diseases of the esophagus. official journal of the International Society for Diseases of the Esophagus. 2009;22(1):9-20. Epub 2008/06/20.   DOI
6 Rafiemanesh H, Maleki F, Mohammadian-Hafshejani A, Salemi M, Salehiniya H. The trend in histological changes and the incidence of esophagus cancer in Iran (2003-2008). Int J Prev Med. 2016;7(1):31.   DOI
7 Enzinger PC, Mayer RJ. Esophageal cancer. The New England journal of medicine. 2003;349(23):2241-2252. Epub 2003/12/06.   DOI
8 Phukan RK, Ali MS, Chetia CK, Mahanta J. Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. British journal of cancer. 2001;85(5):661-667. Epub 2001/09/05.   DOI
9 Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. Journal of pharmacy & pharmaceutical sciences. 2011;14(1):67-77.   DOI
10 Chouhan R, Bajpai A. Real time in vitro studies of doxorubicin release from PHEMA nanoparticles. Journal of nanobiotechnology. 2009;7(1):5.   DOI
11 Bromberg L, Alakhov V. Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. Journal of controlled release. 2003;88(1):11-22.   DOI
12 Gupta RB, Kompella UB. Nanoparticle Technology for Drug Delivery. New York: Taylor and Francic; 2006.
13 Amjadi I, Rabiee M, Hosseini M, Sefidkon F, Mozafari M. Nanoencapsulation of Hypericum perforatum and doxorubicin anticancer agents in PLGA nanoparticles through double emulsion technique. Micro & Nano Letters. 2013;8(5):243-247.   DOI
14 Yu D, Xiao S, Tong C, Chen L, Liu X. Dialdehyde starch nanoparticles: Preparation and application in drug carrier. Chinese Science Bulletin. 2007;52(21):2913-2918.   DOI
15 Bonakdar S, Poursamar SA, Rafienia M, Shokrgozar MA, Farhadi A, Hosseini M. Effect of Freezing and Thawing Process on Betamethasone Acetate Release from Polyvinyl alcohol Nanospheres. Solid State Phenomena. 2009;151:159-165.   DOI
16 Lebold T, Jung C, Michaelis J, Brauchle C. Nanostructured silica materials as drug-delivery systems for doxorubicin: single molecule and cellular studies. Nano letters. 2009;9(8):2877-2883.   DOI
17 Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Journal of Pharmacology and Experimental Therapeutics. 2006;317(3):1372-1381.   DOI
18 Mohajeri M, Sahebkar A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review. Critical Reviews in Oncology/Hematology. 2018;122:30-51.   DOI
19 Soleymani S, Bahramsoltani R, Rahimi R, Abdollahi M. Clinical risks of St John's Wort (Hypericum perforatum) co-administration. Expert opinion on drug metabolism & toxicology. 2017;13(10):1047-1062.   DOI
20 Klemow KM, Bartlow A, Crawford J, Kocher N, Shah J, Ritsick M. Chapter 11: Medical Attributes of St. John's Wort (Hypericum perforatum). In: Benzie I, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis; 2011.
21 Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49(5):330-352.   DOI
22 Dost T, Ozkayran H, Gokalp F, Yenisey C, Birincioglu M. The effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat. Dig Dis Sci. 2009;54(6):1214-1221.   DOI
23 Cayci MK, Dayioglu H. Hypericum perforatum extracts healed gastric lesions induced by hypothermic restraint stress in Wistar rats. Saudi Med J. 2009;30(6):750-754.
24 Zdunic G, Godevac D, Milenkovic M, Vucicevic D, Savikin K, Menkovic N, et al. Evaluation of Hypericum perforatum oil extracts for an antiinflammatory and gastroprotective activity in rats. Phytother Res. 2009;23(11):1559-1564.   DOI
25 Karaarslan S, Cokmert S, Cokmez A. Does St. John's Wort cause regression in gastrointestinal system adenocarcinomas? World Journal of Gastrointestinal Oncology. 2015;7(11):369-374.   DOI
26 Amjadi I, Rabiee M, Hosseini M-S. Anticancer activity of nanoparticles based on PLGA and its co-polymer: in-vitro evaluation. Iranian journal of pharmaceutical research: IJPR. 2013;12(4):623-634.
27 Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepatic oncology. 2016;3(1):57-59.   DOI
28 Zhou S, Chan E, Pan S-Q, Huang M, Lee EJD. Pharmacokinetic interactions of drugs with St John's wort. Journal of Psychopharmacology. 2004;18(2):262-276.   DOI
29 Mannel M. Drug interactions with St John's wort. Drug safety. 2004;27(11):773-797.   DOI
30 Bhadra R, Ravakhah K, Ghosh RK. Herb-drug interaction: The importance of communicating with primary care physicians. The Australasian medical journal. 2015;8(10):315-319.   DOI
31 Saddiqe Z, Naeem I, Maimoona A. A review of the antibacterial activity of Hypericum perforatum L. Journal of ethnopharmacology. 2010;131(3):511-521.   DOI
32 Davids LM, Kleemann B, Kacerovska D, Pizinger K, Kidson SH. Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. Journal of Photochemistry and Photobiology B: Biology. 2008;91(2-3):67-76.   DOI
33 Ozturk N, Korkmaz S, Ozturk Y. Wound-healing activity of St. John's Wort (Hypericum perforatum L.) on chicken embryonic fibroblasts. Journal of ethnopharmacology. 2007;111(1):33-39.   DOI
34 Husain GM, Chatterjee SS, Singh PN, Kumar V. Hypolipidemic and antiobesity-like activity of standardised extract of Hypericum perforatum L. in rats. ISRN pharmacology. 2011;2011:505247.
35 Feily A, Abbasi N. The inhibitory effect of Hypericum perforatum extract on morphine withdrawal syndrome in rat and comparison with clonidine. Phytotherapy research. 2009;23(11):1549-1552.   DOI
36 Zou YP, Lu YH, Wei DZ. Protective effects of a flavonoid-rich extract of Hypericum perforatum L. against hydrogen peroxide-induced apoptosis in PC12 cells. Phytotherapy research. 2010;24(S1):S6-S10.   DOI
37 Van Strater AC, Bogers JP. Interaction of St John's wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol. 2012;27(2):121-124.   DOI
38 Asakura T, Ohkawa K, Takahashi N, Takada K, Inoue T, Yokoyama S. Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and-resistant rat hepatoma cells. British journal of cancer. 1997;76(10):1333.   DOI
39 Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. The AAPS journal. 2009;11(4):710-727.   DOI
40 Lee HH, Ye S, Li XJ, Lee KB, Park MH, Kim SM. Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt. Oncology reports. 2014;31(1):183-188.   DOI
41 Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. Induction of imatinib metabolism by hypericum perforatum. Blood. 2004;104(4):1229-1230.   DOI
42 Clementi ME, Giardina B, Di ES, Mordente A, Misiti F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer research. 2003;23(3B):2445-2450.
43 Marchand DJ, Renton KW. Depression of cytochrome P-450-dependent drug biotransformation by adriamycin. Toxicology and applied pharmacology. 1981;58(1):83-88.   DOI
44 Shibayama Y, Ikeda R, Motoya T, Yamada K. St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study. Food Chem Toxicol. 2004;42(6):995-1002.   DOI
45 Spratlin J, Sawyer MB. Pharmacogenetics of paclitaxel metabolism. Critical Reviews in Oncology/Hematology. 2007;61(3):222-229.   DOI
46 Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clinical Pharmacology & Therapeutics. 2004;76(4):323-329.   DOI
47 Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. Journal of the National Cancer Institute. 2002;94(16):1247-1249.   DOI
48 Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, et al. The effect of St John's wort on the pharmacokinetics of docetaxel. Clinical pharmacokinetics. 2014;53(1):103-110.   DOI